KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Other (2016 - 2020)

Regeneron Pharmaceuticals (REGN) has disclosed Receivables - Other for 12 consecutive years, with $460.8 million as the latest value for Q3 2020.

  • For Q3 2020, Receivables - Other rose 33.41% year-over-year to $460.8 million; the TTM value through Sep 2020 reached $460.8 million, up 33.41%, while the annual FY2019 figure was $260.6 million, 15.11% up from the prior year.
  • Receivables - Other hit $460.8 million in Q3 2020 for Regeneron Pharmaceuticals, up from $389.2 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $468.3 million in Q1 2020 and bottomed at $93.0 million in Q4 2016.
  • Average Receivables - Other over 5 years is $249.8 million, with a median of $226.4 million recorded in 2018.
  • Year-over-year, Receivables - Other tumbled 39.28% in 2016 and then soared 108.3% in 2017.
  • Regeneron Pharmaceuticals' Receivables - Other stood at $93.0 million in 2016, then skyrocketed by 108.3% to $193.7 million in 2017, then grew by 16.88% to $226.4 million in 2018, then rose by 15.11% to $260.6 million in 2019, then skyrocketed by 76.82% to $460.8 million in 2020.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $460.8 million, $389.2 million, and $468.3 million for Q3 2020, Q2 2020, and Q1 2020 respectively.